Last updated on November 2014

Immunogenicity and Safety Study of GSK Biologicals' Priorix® Vaccine (209762) at an End of Shelf-life Potency Compared to Merck & Co., Inc.'s MMR Vaccine When Both Are Given on a 2-dose Schedule to Healthy Children in Their 2nd Year of Life

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: *Healthy Children Studies
  • Age: Between 12 - 15 Years
  • Gender: Male or Female

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.